diagnosis
Patients with clinical symptoms suggesting a neuroendocrine GEP tumour should be referred to a centre with special interest in and knowledge of these diseases. The histopathological diagnosis is performed on tissue samples obtained either by endoscopic biopsy, open surgery or by core needle biopsy from metastatic sites. The family of neuroendocrine GEP tumours constitutes a heterogeneous group, but all share common histochemical features, with immunoreactivity for the so called 'pan-neuroendocrine' markers, including chromogranin A and synaptophysin. The proliferation potential should be evaluated by staining with the proliferation marker Ki-67 (MIB-I). Depending on clinical symptoms, specific hormonal markers can be searched for in the tissue sample, but it must be remembered that there is not always a correlation between tissue expression of hormones and amines and circulating levels. All patients should have an analysis of chromogranin A in plasma as a general tumour marker and depending on clinical symptoms, other markers should be analysed such as urinary 5HIAA for the carcinoid syndrome, gastrin for the Zollinger-Ellison syndrome and insulin/pro-insulin for the hypoglycaemic syndrome. Dynamic stimulation tests may be required in specific cases (fasting test for insulinomas; secretin test for gastrinomas, etc.).
staging and risk assessment
Neuroendocrine tumours arising at different anatomical sites of the digestive system represent tumour entities that differ in their biology and clinical presentation ( Table 1) . The WHO classification system was established in year 2000 (Table 2) , dividing the tumours into well-differentiated endocrine tumour, well-differentiated endocrine carcinoma, poorly differentiated endocrine carcinoma and mixed exocrine and endocrine tumours. Recently the European Neuroendocrine Tumor Society has proposed a TNM staging and grading system for various types of GEP-NET (Tables 3-8) . Preoperative staging should whenever possible include somatostatin receptor scintigraphy (Octreoscan), although it is not equally sensitive for all GEP-NETs. This technique should always be complemented with CT or MRI (depending on the tumour location), which can generally provide more precise anatomical definition if positive. PET Patients with endocrine pancreatic tumours, often present with metastatic disease, except for insulin-producing tumours, which are benign in 85% of cases [II, A] . The largest group of GEP-NETs, well-differentiated (neuro-)endocrine tumours of the small intestine (midgut carcinoids), present with the carcinoid syndrome in 30%, including flushing, diarrhoea and endocardial fibrosis. The 5-year survival rate for patients with endocrine pancreatic tumours is estimated to be 60%-100% for localized disease, 40% for regional, 25% for metastatic and 80% for all stages. Similarly for 'classical' midgut carcinoids, the 5-year survival rate has been 60% for all stages.
Patients with high-grade poorly differentiated (neuro-) endocrine carcinomas present a median survival of only 10 months. In multivariate analyses of prognostic factors in GEPNETs, pancreatic localization, poor degree of differentiation and distant metastases were negative prognostic factors [II, A].
treatment plan localized disease
Surgery is the primary treatment for localized tumours and might be curative providing 5-year survival rates of 80%-100% in resectable cases. It is so far the only curative treatment [II, A]. Table 1 . Classification of neuroendocrine GEP tumours (GEP-NETs) by site of origin and by hormonal activity Intestinal neuroendocrine tumours (carcinoids, about two-thirds of GEPNETs) with carcinoid syndrome (30% of carcinoids) without carcinoid syndrome (70% of carcinoids) Pancreatic endocrine tumours (PETs) (about one-third of GEP-NETs)
Non-functioning (45%-60% of PETs) Functioning (40%-55% of PETs) Gastrinoma, excessive gastrin production, Zollinger-Ellison syndrome Insulinoma, excessive insulin production, hypoglycaemia syndrome Glucagonoma, excessive glucagon production, glucagonoma syndrome VIPoma, excessive production of vasoactive intestinal peptide (VIP), watery diarrhoea, hypokalaemia-achlorhydria (WDHA) syndrome PPoma, excessive pancreatic polypeptide (PP) production, (generally classified as non-functioning PETs) Somatostatinoma, excessive somatostatin production CRHoma, excessive corticotropin-releasing hormone (CRH) production Calcitoninoma, excessive calcitonin production GHRHoma, excessive growth hormone-releasing hormone (GHRH) production Neurotensinoma, excessive neurotensin production ACTHoma, excessive production of adrenocorticotropic hormone (ACTH) GRFoma, excessive production of growth hormone-releasing factor (GRF) Parathyroid hormone-related peptide tumour Cytotoxic treatment has been of limited value for the treatment of low-proliferating GEP-NET tumours, such as the typical midgut carcinoids (response rates 10%-15%), but has been the standard of care for malignant endocrine pancreatic tumours (with response rates 30%-50%). Currently the following cytotoxic agents are applied: streptozotocin plus 5-flurouracil (5FU)/doxorubicin (response rates 30%), temozolomide alone or in combination with capecitabine (RR 35%-40%). Poorly differentiated tumours (WHO group 3) are mostly treated with cisplatinum/oxaliplatin plus etoposide (response rates 40%-60%) usually of short duration (Table 9) .
Biological treatment, such as somatostatin analogues and a-interferons has proved effective in the control of associated clinical syndromes related to hormone production and release (carcinoid syndrome, VIPoma and glucagonoma syndrome). Their use in non-functioning tumours has been debated, but Peptide receptor radiotherapy (PRRT) treatment is an option in patients who present with high-grade uptake on somatostatin receptor scintigraphy [III, B] . The precise role of PRRT has to be defined by future randomized trials and is usually applied as second-line therapy. Recently antiangiogenic agents (bevacizumab, sunitinib) and m-TOR inhibitors (RAD001, everolimus) have been applied in GEP-NETs with objective response rates of 10%-20%. A treatment algorithm is presented in Figure 1 . This algorithm is based on the WHO classification and the ENETS guidelines for treatment of GI-NETs.
response evaluation
Response to current treatment should be evaluated by both biochemical markers and imaging. Chromogranin A is an important and stable marker that can be followed during longterm treatment, in both functioning and non-functioning tumours; CT scans or MRI are standards for treatment evaluation.
follow-up
Patients with malignant neuroendocrine tumours are usually followed at 3-month intervals during treatment with cytotoxic agents or biological therapy to evaluate the treatment response. The same is true for treatment with PRRT. Patients undergoing curative surgery should be followed every 3-6 months for >5 years. Biochemical testing is suggested every 3 months and imaging every 6 months. clinical practice guidelines Annals of Oncology
